{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:42:40Z","timestamp":1760182960059,"version":"build-2065373602"},"reference-count":140,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1016\/j.rdc.2006.02.002","type":"journal-article","created":{"date-parts":[[2007,1,10]],"date-time":"2007-01-10T10:09:23Z","timestamp":1168423763000},"page":"359-382","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical Trials in Crystal Arthropathy"],"prefix":"10.1016","volume":"32","author":[{"given":"Nancy","family":"Joseph-Ridge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Cazzetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rdc.2006.02.002_bib1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0011-5029(94)90021-3","article-title":"Crystals and arthritis","volume":"40","author":"McCarty","year":"1994","journal-title":"Dis Mon"},{"key":"10.1016\/j.rdc.2006.02.002_bib2","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1053\/berh.2000.0087","article-title":"Gout and other crystal-associated arthropathies","volume":"14","author":"McGill","year":"2000","journal-title":"Baillieres Clin Rheumatol"},{"key":"10.1016\/j.rdc.2006.02.002_bib3","series-title":"Kelley's textbook of rheumatology","first-page":"1402","article-title":"Gout and hyperuricemia","author":"Wortmann","year":"2005"},{"key":"10.1016\/j.rdc.2006.02.002_bib4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0889-857X(21)00376-8","article-title":"Treatment of refractory crystal-associated arthritis","volume":"21","author":"Rosenthal","year":"1995","journal-title":"Rheum Dis Clin North Am"},{"issue":"2A","key":"10.1016\/j.rdc.2006.02.002_bib5","doi-asserted-by":"crossref","first-page":"46S","DOI":"10.1016\/S0002-9343(97)89546-0","article-title":"Crystal-induced arthritis: an overview","volume":"100","author":"Schumacher","year":"1996","journal-title":"Am J Med"},{"key":"10.1016\/j.rdc.2006.02.002_bib6","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00002281-199206000-00002","article-title":"Treatment of gout and crystal arthropathies and uses and mechanisms of action of nonsteroidal anti-inflammatory drugs","volume":"4","author":"Abramson","year":"1992","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.rdc.2006.02.002_bib7","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11926-004-0074-4","article-title":"Treatment of acute gouty arthritis: one physician's approach and where this management stands relative to developments in the field","volume":"6","author":"Wortmann","year":"2004","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.rdc.2006.02.002_bib8","first-page":"231","article-title":"What is the optimal treatment for acute crystal-induced arthritis?","volume":"63","author":"Pawlotsky","year":"1996","journal-title":"Rev Rheum [English edition]"},{"key":"10.1016\/j.rdc.2006.02.002_bib9","first-page":"961","article-title":"Hyperuricaemia and gout: clinical guidelines 2003","volume":"93","author":"Meyers","year":"2003","journal-title":"S Afr Med J"},{"key":"10.1016\/j.rdc.2006.02.002_bib10","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.2165\/00003495-200464210-00003","article-title":"Management of acute and chronic gouty arthritis: present state-of-the-art","volume":"64","author":"Schlesinger","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.rdc.2006.02.002_bib11","first-page":"1161","article-title":"Therapie des akuten gichtanfalls mit acemetacin","volume":"35","author":"Dorfler","year":"1985","journal-title":"Therapiewock"},{"key":"10.1016\/j.rdc.2006.02.002_bib12","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/art.1780190225","article-title":"Ibuprofen in acute polyarticular gout [letter]","volume":"19","author":"Franck","year":"1976","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2006.02.002_bib13","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1001\/jama.1978.03280280034020","article-title":"Ibuprofen in the treatment of acute gouty arthritis","volume":"239","author":"Schweitz","year":"1978","journal-title":"JAMA"},{"key":"10.1016\/j.rdc.2006.02.002_bib14","first-page":"82","article-title":"Comparison of indomethacin and phenylbutazone in acute gout","volume":"29","author":"Smyth","year":"1973","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2006.02.002_bib15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1177\/030006057900700113","article-title":"Oxamethacin: a pilot field survey","volume":"7","author":"Polderman","year":"1979","journal-title":"J Int Med Res"},{"key":"10.1016\/j.rdc.2006.02.002_bib16","first-page":"15","article-title":"Treatment of acute gouty arthritis with proquazone and indomethacin: a comparative double-blind trial","volume":"21","author":"Ruosti","year":"1978","journal-title":"Scand J Rheumatol Suppl"},{"key":"10.1016\/j.rdc.2006.02.002_bib17","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/0002-9343(86)90131-2","article-title":"Flurbiprofen in the treatment of acute gout. A comparison with indomethacin","volume":"80","author":"Lomen","year":"1986","journal-title":"Am J Med"},{"key":"10.1016\/j.rdc.2006.02.002_bib18","first-page":"1422","article-title":"Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study","volume":"15","author":"Altman","year":"1988","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rdc.2006.02.002_bib19","first-page":"409","article-title":"Comparative trial of azapropazone and indomethacin plus allopurinol in acute gout and hyperuricemia","volume":"37","author":"Fraser","year":"1987","journal-title":"J R Coll Gen Pract"},{"key":"10.1016\/j.rdc.2006.02.002_bib20","first-page":"641","article-title":"Meclofenomate sodium in the treatment of acute gout","volume":"33","author":"Eberl","year":"1983","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.rdc.2006.02.002_bib21","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/art.1780220420","article-title":"Double blind study of phenoprofen versus phenylbutazone in acute gouty arthritis","volume":"22","author":"Weiner","year":"1979","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2006.02.002_bib22","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/art.1780190516","article-title":"Effect of fenoprofen calcium on acute gouty arthritis","volume":"19","author":"Wanasukapent","year":"1976","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2006.02.002_bib23","first-page":"92","article-title":"Estudio doble-ciego paralelo, comparativo con tenaxicam vs placebo en artritis gotosa aguda [Double-blind parallel-study comparin tenoxicam and placebo in acute gouty arthritis]","volume":"14","author":"Garcia de la Torre","year":"1987","journal-title":"Invest Med Int"},{"key":"10.1016\/j.rdc.2006.02.002_bib24","first-page":"297","article-title":"Sulindac in the treatment of acute gouty arthritis","volume":"4","author":"Karachalios","year":"1982","journal-title":"Int J Tiss Res"},{"key":"10.1016\/j.rdc.2006.02.002_bib25","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0149-2918(04)90035-5","article-title":"A single-blind, randomized, controlled trial to assess the efficacy and tolerability of rofecoxib, diclofenac sodium, and meloxicam in patients with acute gouty arthritis","volume":"26","author":"Cheng","year":"2004","journal-title":"Clin Ther"},{"key":"10.1016\/j.rdc.2006.02.002_bib26","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/art.20007","article-title":"Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial","volume":"50","author":"Rubin","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2006.02.002_bib27","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1136\/bmj.324.7352.1488","article-title":"Randomized double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis","volume":"324","author":"Schumacher","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.rdc.2006.02.002_bib28","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/0735-6757(94)90061-2","article-title":"Treatment of acute gouty arthritis with intramuscular ketorolac tromethamine","volume":"12","author":"Shrestha","year":"1994","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.rdc.2006.02.002_bib29","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S0196-0644(95)70037-4","article-title":"Randomized double-blind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis","volume":"26","author":"Strestha","year":"1995","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.rdc.2006.02.002_bib30","first-page":"344","article-title":"A double-blind comparison of etodolac (Lodine) and high doses of naproxen in the treatment of acute gout","volume":"7","author":"Lederman","year":"1990","journal-title":"Adv Ther"},{"key":"10.1016\/j.rdc.2006.02.002_bib31","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1185\/03007999109111513","article-title":"Effectiveness of etodolac (Lodine) compared with naproxen in patients with acute gout","volume":"12","author":"Maccagno","year":"1991","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.rdc.2006.02.002_bib32","first-page":"804","article-title":"Colchicine prophylaxis in pseudogout","volume":"13","author":"Alvarellos","year":"1986","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rdc.2006.02.002_bib33","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1445-5994.1987.tb01232.x","article-title":"Does colchicine work? The results of the first controlled study in acute gout","volume":"17","author":"Ahern","year":"1987","journal-title":"Aust N Z J Med"},{"key":"10.1016\/j.rdc.2006.02.002_bib34","first-page":"925","article-title":"Gout and hyperuricemia","volume":"59","author":"Harris","year":"1999","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.rdc.2006.02.002_bib35","doi-asserted-by":"crossref","first-page":"735","DOI":"10.7326\/0003-4819-39-4-735","article-title":"Intra-articular hydrocortisone in the treatment of arthritis","volume":"39","author":"Hollander","year":"1953","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rdc.2006.02.002_bib36","first-page":"190","article-title":"Intra-articular corticosteroid therapy","volume":"12","author":"Hollander","year":"1961","journal-title":"Am Pract"},{"key":"10.1016\/j.rdc.2006.02.002_bib37","first-page":"65","article-title":"Current concepts of pathogenesis of rheumatoid arthritis","volume":"41","author":"Hollander","year":"1969","journal-title":"Del Med J"},{"key":"10.1016\/j.rdc.2006.02.002_bib38","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0049-0172(81)90001-9","article-title":"Local corticosteroid injection treatment in rheumatic disorders","volume":"10","author":"Gray","year":"1981","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.rdc.2006.02.002_bib39","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/00003086-198307000-00036","article-title":"Intra-articular corticosteroids: an updated assessment","volume":"177","author":"Gray","year":"1983","journal-title":"Clin Orthop"},{"key":"10.1016\/j.rdc.2006.02.002_bib40","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0049-0172(90)90070-V","article-title":"Systemic steroid therapy for acute gout: a clinical trial and review of the literature","volume":"19","author":"Groff","year":"1990","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.rdc.2006.02.002_bib41","first-page":"248","article-title":"Corticosteroid therapy for the treatment of acute attacks of crystal-induced arthritis: an effective alternative to nonsteroidal anti-inflammatory drugs","volume":"63","author":"Werlen","year":"1996","journal-title":"Rev Rhum"},{"key":"10.1016\/j.rdc.2006.02.002_bib42","first-page":"677","article-title":"Prospective use of intramuscular triamcinolone acetonide in pseudogout","volume":"150","author":"Roane","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rdc.2006.02.002_bib43","first-page":"111","article-title":"Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis","volume":"20","author":"Alloway","year":"1993","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rdc.2006.02.002_bib44","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/art.1780310618","article-title":"Comparison of parenteral adrenocrticostropic hormone with oral indomethacin in the treatment of acute gout","volume":"31","author":"Axelrod","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2006.02.002_bib45","first-page":"1766","article-title":"Rapid treatment of acute gouty arthritis by concurrent administration of pituitary adrenocorticotropic hormone (ACTH) and colchicine","volume":"34","author":"Wolfson","year":"1949","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.rdc.2006.02.002_bib46","first-page":"322","article-title":"Terapia dell'attacco gottoso con ACTH sinetico ad azione ritardata [Therapy of gout attacks with synthetic delayed-action ACTH]","volume":"77","author":"Muzzolini","year":"1970","journal-title":"Policlinico [Med]"},{"key":"10.1016\/j.rdc.2006.02.002_bib47","first-page":"696","article-title":"ACTH revisited: effective treatment of acute crystal induced synovitis in patients with multiple medical problems","volume":"21","author":"Ritter","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rdc.2006.02.002_bib48","first-page":"S225","article-title":"The use of parenteral ACTH for acute crystal-induced synovitis in patients with multiple medical problems","volume":"35","author":"Ritter","year":"1992","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2006.02.002_bib49","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1345\/aph.10230","article-title":"Corticotropin for acute management of gout","volume":"35","author":"Taylor","year":"2001","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.rdc.2006.02.002_bib50","first-page":"1325","article-title":"Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of gouty arthritis","volume":"21","author":"Siegel","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rdc.2006.02.002_bib51","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/S0149-2918(03)80158-3","article-title":"A literature review of the epidemiology and treatment of acute gout","volume":"25","author":"Kim","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.rdc.2006.02.002_bib52","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1136\/ard.2003.015743","article-title":"Severe gouty arthritis refractory to anti-inflammatory drugs: treatment with anti-tumour necrosis factor alpha as a new therapeutic option","volume":"63","author":"Tausche","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2006.02.002_bib53","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s00296-003-0408-y","article-title":"Lack of evidence for inhibition of angiogenesis as a central mechanism of the antiarthritic effect of methotrexate","volume":"25","author":"Fiehn","year":"2005","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.rdc.2006.02.002_bib54","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/0003-4819-55-2-179","article-title":"Efficacy of colchicine prophylaxis in gout. Prevention of recurrent gouty arthritis over a mean period of five years in 208 gouty subjects","volume":"55","author":"Yu","year":"1961","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rdc.2006.02.002_bib55","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/0049-0172(82)90065-8","article-title":"The efficacy of colchicine prophylaxis in articular gout\u2014a reappraisal after 20 years","volume":"12","author":"Yu","year":"1982","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.rdc.2006.02.002_bib56","first-page":"577","article-title":"Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout?","volume":"28","author":"Li-Yu","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rdc.2006.02.002_bib57","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/art.1780170517","article-title":"Prophylactic colchicine therapy of intercritical gout. A placebo-controlled study of probenecid-treated patients","volume":"17","author":"Paulus","year":"1974","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2006.02.002_bib58","first-page":"2429","article-title":"Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis","volume":"31","author":"Borstad","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rdc.2006.02.002_bib59","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/art.10455","article-title":"A randomized controlled trial to evaluate the slow-acting symptom modifying effects of colchicine in osteoarthritis of the knee. A preliminary report","volume":"47","author":"Das","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2006.02.002_bib60","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/art.20935","article-title":"Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout","volume":"52","author":"Becker","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2006.02.002_bib61","first-page":"S335","article-title":"Gout flare prophylaxis during management of chronic gout with febuxostat, a non-purine selective inhibitor of xanthine oxidase","volume":"50","author":"Wortmann","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2006.02.002_bib62","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rdc.2006.02.002_bib63","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/BF02201004","article-title":"Withdrawal of long-term antihyperuricemic therapy in tophaceous gout","volume":"6","author":"Gast","year":"1987","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.rdc.2006.02.002_bib64","first-page":"1383","article-title":"Withdrawal of long-term antihyperuricemic therapy in tophaceous gout","volume":"20","author":"Van Lieshout-Zuidema","year":"1993","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rdc.2006.02.002_bib65","first-page":"1246","article-title":"Intermittent control of hyperuricemia in the treatment of gout","volume":"16","author":"Bull","year":"1989","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rdc.2006.02.002_bib66","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.10511","article-title":"Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout","volume":"47","author":"Perez-Ruiz","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2006.02.002_bib67","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/ard.57.9.545","article-title":"Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout","volume":"57","author":"Perez-Ruiz","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2006.02.002_bib68","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/art.20405","article-title":"A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy","volume":"51","author":"Shoji","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2006.02.002_bib69","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1172\/JCI102505","article-title":"Effect of benemid (p-[di-n-propylsulfamyl]-benzoic acid) on uric acid metabolism in one normal and one gouty subject","volume":"30","author":"Bishop","year":"1951","journal-title":"J Clin Invest"},{"key":"10.1016\/j.rdc.2006.02.002_bib70","first-page":"623","article-title":"Comparison of allopurinol to probenecid","volume":"25","author":"Scott","year":"1966","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2006.02.002_bib71","doi-asserted-by":"crossref","first-page":"252","DOI":"10.2165\/00002018-199411040-00004","article-title":"Risks and benefits of drugs used in the management and prevention of gout","volume":"11","author":"Conaghan","year":"1994","journal-title":"Drug Saf"},{"key":"10.1016\/j.rdc.2006.02.002_bib72","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1388-9842(02)00086-7","article-title":"The management of hyperuricemia and gout in patients with heart failure","volume":"4","author":"Spieker","year":"2002","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.rdc.2006.02.002_bib73","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1177\/030006058100900615","article-title":"Benzbromarone therapy in hyperuricaemia: comparison with allopurinol and probenecid","volume":"9","author":"Schepers","year":"1981","journal-title":"J Int Med Res"},{"key":"10.1016\/j.rdc.2006.02.002_bib74","first-page":"1212","article-title":"Effect of uric acid lowering drugs in low dosage in patients with hyperuricemia and hypertriglyceridemia in a randomized group study","volume":"97","author":"Arntz","year":"1979","journal-title":"Fortschr Med"},{"key":"10.1016\/j.rdc.2006.02.002_bib75","first-page":"719","article-title":"Effectiveness and tolerance of long-erm uricosuric treatment","volume":"45","author":"Berg","year":"1990","journal-title":"Z Gesamte Inn Med"},{"key":"10.1016\/j.rdc.2006.02.002_bib76","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0168-8278(94)80011-1","article-title":"Hepatic injury caused by benzbromarone","volume":"20","author":"van der Klauw","year":"1994","journal-title":"J Hepatol"},{"key":"10.1016\/j.rdc.2006.02.002_bib77","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0168-8278(05)80159-X","article-title":"Subfulminant hepatitis requiring liver transplantation after benzarone administration","volume":"20","author":"Gehenot","year":"1994","journal-title":"J Hepatol"},{"key":"10.1016\/j.rdc.2006.02.002_bib78","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1600-0676.1995.tb00102.x","article-title":"Severe hepatotoxicity related to benzarone: a report of three cases with two fatalities","volume":"15","author":"Hautekeete","year":"1995","journal-title":"Liver"},{"key":"10.1016\/j.rdc.2006.02.002_bib79","doi-asserted-by":"crossref","first-page":"535","DOI":"10.5694\/j.1326-5377.1989.tb128510.x","article-title":"A survey of the current prescribing practices of anti-inflammatory and urate lowering drugs in gouty arthritis in New South Wales and Queensland","volume":"151","author":"Bellamy","year":"1989","journal-title":"Med J Aust"},{"key":"10.1016\/j.rdc.2006.02.002_bib80","first-page":"155","article-title":"The efficacy of treatment with allopurinol versus uricosuric drugs in gout","volume":"20","author":"Weinberger","year":"1978","journal-title":"Panminerva Med"},{"key":"10.1016\/j.rdc.2006.02.002_bib81","doi-asserted-by":"crossref","first-page":"229","DOI":"10.7326\/0003-4819-64-2-229","article-title":"Allopurinol in the treatment of gout","volume":"64","author":"Rundles","year":"1966","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rdc.2006.02.002_bib82","first-page":"595","article-title":"Treatment with allopurinol decreases the number of acute gout attacks despite persistently elevated serum uric acid [letter]","volume":"19","author":"Beutler","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.rdc.2006.02.002_bib83","first-page":"1232","article-title":"The misdiagnosis of gout and hyperuricemia","volume":"18","author":"Wolf","year":"1991","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rdc.2006.02.002_bib84","first-page":"1841","article-title":"A survey of current prescribing practices of antiinflammatory and urate lowering drugs in gouty arthritis in the province of Ontario","volume":"15","author":"Bellamy","year":"1988","journal-title":"J Rheumatol"},{"issue":"Suppl","key":"10.1016\/j.rdc.2006.02.002_bib85","first-page":"S86","article-title":"Allopurinol may have protective effect against acute gouty arthritis independent from its hypouricemic action","volume":"39","author":"Beutler","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2006.02.002_bib86","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/106002809302700317","article-title":"Allopurinol hypersensitivity syndrome. A review","volume":"27","author":"Arellano","year":"1993","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.rdc.2006.02.002_bib87","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/art.1780290111","article-title":"The allopurinol hypersensitivity syndrome, unnecessary morbidity and mortality","volume":"29","author":"Singer","year":"1986","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2006.02.002_bib88","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity: description and guidelines for prescription in patients with renal insufficiency","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"key":"10.1016\/j.rdc.2006.02.002_bib89","first-page":"114","article-title":"Allopurinol: actions, adverse reactions, and drug interaction","volume":"6","author":"Adriani","year":"1985","journal-title":"Intern Med"},{"key":"10.1016\/j.rdc.2006.02.002_bib90","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archinte.1974.00320210163026","article-title":"Severe allopurinol hypersensitivity syndrome. Association with thiazides and prior renal compromise","volume":"134","author":"Young","year":"1974","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.rdc.2006.02.002_bib91","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0190-9622(79)70031-4","article-title":"The allopurinol hypersensitivity syndrome","volume":"1","author":"Lupton","year":"1979","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.rdc.2006.02.002_bib92","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1002\/art.20438","article-title":"Gout: on the brinkof novel therapeutic options for an ancient disease","volume":"50","author":"Bieber","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2006.02.002_bib93","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/1529-0131(200101)44:1<231::AID-ANR30>3.0.CO;2-7","article-title":"Efficacy and safety of desenstization to allopurinol following cutaneous reactions","volume":"44","author":"Fam","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2006.02.002_bib94","doi-asserted-by":"crossref","first-page":"333","DOI":"10.7326\/0003-4819-85-3-333","article-title":"Allergic reaction to allopurinol with cross-reactivity to oxypurinol","volume":"85","author":"Lockard","year":"1976","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rdc.2006.02.002_bib95","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/BF00192382","article-title":"Disposition and uric acid lowering effect of oxipurinol: comparison of different oxipurinol formulations and allopurinol in healthy individuals","volume":"49","author":"Walter-Sack","year":"1995","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.rdc.2006.02.002_bib97","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1074\/jbc.M208307200","article-title":"An extremely potent inhibitor of xanthine oxidoreductase","volume":"278","author":"Okamoto","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.rdc.2006.02.002_bib98","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.lfs.2004.10.031","article-title":"Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase\/xanthine dehydrogenase","volume":"76","author":"Takano","year":"2005","journal-title":"Life Sci"},{"key":"10.1016\/j.rdc.2006.02.002_bib99","first-page":"307","article-title":"A comparative study on the hypouricemic activity and potency in renal xanthine calculus formation of two xanthine oxidase\/xanthine dehydrogenase inhibitors: TEI-6720 and allopurinol in rats","volume":"104","author":"Horiuchi","year":"1999","journal-title":"Res Commun Mol Pathol Pharmacol"},{"key":"10.1016\/j.rdc.2006.02.002_bib100","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0014-2999(93)90201-R","article-title":"Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents","volume":"241","author":"Osada","year":"1993","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.rdc.2006.02.002_bib101","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1081\/NCN-200027372","article-title":"Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers","volume":"23","author":"Becker","year":"2004","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.rdc.2006.02.002_bib102","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0024-3205(00)00532-4","article-title":"Allopurinol induces renal toxicity by impairing pyrimidine metabolism in mice","volume":"66","author":"Horiuchi","year":"2000","journal-title":"Life Sci"},{"key":"10.1016\/j.rdc.2006.02.002_bib103","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/BF01968126","article-title":"Inhibition of purine nucleoside phosphorylase activity and of T-cell function with allopurinol-riboside","volume":"9","author":"Nishida","year":"1979","journal-title":"Agents Actions"},{"key":"10.1016\/j.rdc.2006.02.002_bib104","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000028344","article-title":"Effect of TEI-6720, a xanthine oxidase inhibitor, on the nucleoside transport in the lung cancer cell line A549","volume":"60","author":"Yamamoto","year":"2000","journal-title":"Pharmacology"},{"key":"10.1016\/j.rdc.2006.02.002_bib105","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/00045391-200501000-00005","article-title":"Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment","volume":"12","author":"Mayer","year":"2005","journal-title":"Am J Ther"},{"key":"10.1016\/j.rdc.2006.02.002_bib106","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1081\/NCN-200027377","article-title":"PK\/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment","volume":"23","author":"Hoshide","year":"2004","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.rdc.2006.02.002_bib107","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1177\/0091270005282634","article-title":"The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel non-purine selective inhibitor of xanthine oxidase","volume":"46","author":"Khosravan","year":"2006","journal-title":"J Clin Pharmacol"},{"issue":"9 Suppl","key":"10.1016\/j.rdc.2006.02.002_bib108","first-page":"S335","article-title":"A phase 2, long term open-label safety and efficacy study of febuxostat, a novel non-purine selective inhibitor of xanthine oxidase [abstract]","volume":"50","author":"Schumacher","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2006.02.002_bib109","first-page":"S680","article-title":"Febuxostat vs. Allopurinol and placebo in subjects with hyperuricemia and gout: the 28-week APEX study","volume":"52","author":"Schumacher","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"9 Suppl","key":"10.1016\/j.rdc.2006.02.002_bib110","first-page":"S530","article-title":"Phase II dose-response clinical trial using febuxostat (TMX-67), a novel-type xanthine oxidase\/xanthine dehydrogenase inhibitor, for gout and hyperuricemia [abstract]","volume":"48","author":"Kamantani","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"9 Suppl","key":"10.1016\/j.rdc.2006.02.002_bib111","first-page":"S337","article-title":"Febuxostat, a novel non-purine selective inhibitor of xanthine oxidase, in a phase III placebo-controlled double-blind clinical trial in Japanese subjects with gout or hyperuricemia [abstract]","volume":"50","author":"Kamatani","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"9 Suppl","key":"10.1016\/j.rdc.2006.02.002_bib112","first-page":"S336","article-title":"Febuxostat, a novel non-purine selective inhibitor of xanthine-oxidase, in an allopurinol-controlled phase III clinical trial in Japanese subjects with gout or hyperuricemia [abstract]","volume":"50","author":"Kamatani","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2006.02.002_bib113","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1517\/14656566.3.4.433","article-title":"Rasburicase: a potent uricolytic agent","volume":"3","author":"Pui","year":"2002","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.rdc.2006.02.002_bib114","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.amjmed.2003.09.045","article-title":"Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome","volume":"116","author":"Davidson","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.rdc.2006.02.002_bib115","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/ndt\/gfh629","article-title":"Urate oxidase (rasburicase) for treatment of severe tophaceous gout","volume":"20","author":"Vogt","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.rdc.2006.02.002_bib116","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1182\/blood.V97.10.2998","article-title":"A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis","volume":"97","author":"Goldman","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.rdc.2006.02.002_bib117","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1200\/JCO.2001.19.3.697","article-title":"Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma","volume":"19","author":"Pui","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rdc.2006.02.002_bib118","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1038\/sj.leu.2402235","article-title":"Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial","volume":"15","author":"Pui","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.rdc.2006.02.002_bib119","first-page":"1942","article-title":"Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies","volume":"29","author":"Bomalaski","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rdc.2006.02.002_bib120","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1681\/ASN.V1251001","article-title":"Diabetes insipidus in uricase-deficient mice: a model for evaluating therapy with poly(ethylene glycol)-modified uricase","volume":"12","author":"Kelly","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.rdc.2006.02.002_bib122","doi-asserted-by":"crossref","first-page":"114","DOI":"10.7326\/0003-4819-109-2-114","article-title":"Use of polyethylene glycol-modified uricase (PED-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma","volume":"109","author":"Chua","year":"1988","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rdc.2006.02.002_bib123","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s11926-004-0075-3","article-title":"Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase","volume":"6","author":"Bomalaski","year":"2004","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.rdc.2006.02.002_bib125","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1136\/ard.60.10.984a","article-title":"Fenofibrate; a new treatment for hyperuricemia and gout?","volume":"60","author":"Hepburn","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2006.02.002_bib126","first-page":"2294","article-title":"Effect of fenofibrate on plasma concentration and urinary excretion of purine bases and oxypurinol","volume":"28","author":"Yamamoto","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rdc.2006.02.002_bib127","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1136\/ard.62.6.572","article-title":"Effects of combination treatment using anti-hyperuricemic agents with fenofibrate and\/or losartan on uric acid metabolism","volume":"62","author":"Takahashi","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2006.02.002_bib128","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/rheumatology\/keg103","article-title":"Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricemia and gout","volume":"42","author":"Feher","year":"2003","journal-title":"Rheumatol"},{"key":"10.1016\/j.rdc.2006.02.002_bib129","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/01.bor.0000162060.25895.a5","article-title":"Recent advances in the management of gout and hyperuricemia","volume":"17","author":"Wortmann","year":"2005","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.rdc.2006.02.002_bib130","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/00041552-200209000-00001","article-title":"Part 1. Uric acid and losartan","volume":"11","author":"Sica","year":"2002","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.rdc.2006.02.002_bib131","first-page":"417","article-title":"Influence of the angiotensin II receptor antagonist losartan on diuretic-induced metabolic effects in elderly hypertensive patients: comparison with a calcium channel blocker","volume":"39","author":"Ohnishi","year":"2001","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.rdc.2006.02.002_bib132","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1097\/00007890-200108270-00019","article-title":"Uricosuric effect of losartan in patients with renal transplants","volume":"72","author":"Kamper","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.rdc.2006.02.002_bib133","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/00007890-199807270-00023","article-title":"Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients","volume":"66","author":"Minghelli","year":"1998","journal-title":"Transplantation"},{"key":"10.1016\/j.rdc.2006.02.002_bib134","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1111\/j.1523-1755.2004.00484.x","article-title":"The impact of serum uric acid on cardiovascular outcomes in the LIFE study","volume":"65","author":"H\u00f8leggen","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.rdc.2006.02.002_bib135","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1001\/archinte.164.14.1546","article-title":"Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study","volume":"164","author":"Niskanen","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.rdc.2006.02.002_bib136","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.0954-6820.1988.tb19625.x","article-title":"Hyperuricemia and risk of cardiovascular disease and overall death. A 12-year follow-up of participants in the population study of women in Gothenburg, Sweden","volume":"224","author":"Bengtsson","year":"1988","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.rdc.2006.02.002_bib137","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/01.STR.29.3.635","article-title":"Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus","volume":"29","author":"Lehto","year":"1998","journal-title":"Stroke"},{"key":"10.1016\/j.rdc.2006.02.002_bib138","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/(SICI)1099-081X(199903)20:2<77::AID-BDD154>3.0.CO;2-D","article-title":"Mechanism of the uricosuric action of the anti-inflammatory drug E3040 used to treat inflammatory bowel disease I: study using a rat model of hyperuricemia","volume":"20","author":"Yamada","year":"1999","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.rdc.2006.02.002_bib139","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S0960-894X(01)00093-2","article-title":"Synthesis and structure-activity relationships of 1-phenylpyrazoles as xanthine oxidase inhibitors","volume":"11","author":"Isibuchi","year":"2001","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.rdc.2006.02.002_bib140","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1081\/NCN-200027384","article-title":"Pharmacokinetics\/pharmacodynamics of Y-700, a novel xanthine oxidase inhibitor, in rats and man","volume":"23","author":"Yamada","year":"2004","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"Suppl","key":"10.1016\/j.rdc.2006.02.002_bib141","first-page":"S530","article-title":"Pharmacokinetics and pharmacodynamics of Y-700, a potent and non-renal excretion type of xanthine oxidase inhibitor, in healthy male volunteers","volume":"48","author":"Osajima","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"Suppl","key":"10.1016\/j.rdc.2006.02.002_bib142","first-page":"S530","article-title":"Safety, tolerability, pharmacokinetics and lowering uric acid effect of repeated daily dosing with Y-700, a novel xanthine oxidase inhibitor, in healthy male volunteers","volume":"48","author":"Noma","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2006.02.002_bib143","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1055\/s-2005-837789","article-title":"Hypouricemic action of scopoletin arising from xanthine oxidase inhibition and uricosuric activity","volume":"71","author":"Ding","year":"2005","journal-title":"Planta Med"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X06000196?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X06000196?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:04:59Z","timestamp":1760180699000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X06000196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":140,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["S0889857X06000196"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2006.02.002","relation":{},"ISSN":["0889-857X"],"issn-type":[{"type":"print","value":"0889-857X"}],"subject":[],"published":{"date-parts":[[2006,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Trials in Crystal Arthropathy","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2006.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}